A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING ATEZOLIZUMAB AND BEVACIZUMAB, WITH OR WITHOUT TIRAGOLUMAB, IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA

The purpose of this study is to compare the effects, good or bad, of tiragolumab plus atezolizumab plus bevacizumab versus placebo plus atezolizumab plus bevacizumab on patients with HCC. In this study, participants will be randomized you will get either tiragolumab plus atezolizumab plus bevacizumab or placebo plus atezolizumab plus bevacizumab. A placebo looks like a drug but has no active ingredient.Tiragolumab has not been approved by FDA to treat HCC. Atezolizumab plus bevacizumab is currently the standard of care.

Are you Eligible? (Inclusion Criteria)

• Age 18 years or older at the time of signing informed consent form - Ability to comply with the study protocol, in the investigator's judgment - Disease that is not amenable to curative surgical and/or locoregional therapies